Pancreatic Cancer Research

Clinical trialPhase 2 / Phase 3Unknown

Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Combined With Pd-1 Antibody

Exploratory Clinical Study on the Second-line and Above Treatment of Advanced Solid Tumor With Anlotinib Hydrochloride Combined With Pd-1 Antibody: An Open-Label, Single-center, Single-arm Study

Outcome
Outcome unknown
Phase
Phase 2 / Phase 3
Status
Unknown
Study type
Interventional
Start
8 April 2019
Listed end
8 July 2021
Enrollment
100 participants
Sites
1
Primary outcomes
Progression-free Survival (PFS)
Sponsor type
Other government
Results posted
No
Last update
5 June 2019

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

The main objective was to evaluate the safety and efficacy of anlotinib hydrochloride combined with pd-1 antibody second-line and above in the treatment of advanced solid tumors

Detailed description public domain (ClinicalTrials.gov)

To observe the beneficial population and adverse reactions of anlotinib hydrochloride combined with pd-1 in the treatment of patients with advanced solid tumor, and to explore the safe and effective drug treatment dose in the combined program, so that more patients with advanced tumor with poor prognosis can benefit from the combined program